Novartis Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Novartis Quarterly Results    (NVRT)

Here are the latest quarterly results of Novartis. For more details, see the Novartis financial fact sheet and Novartis share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Novartis Quarterly Results

No. of Mths
Qtr. Ending
3
Jun-18
3
Sep-18
3
Dec-18
3
Mar-19
3
Jun-19
3
Sep-19
3
Dec-19
3
Mar-20
8-Qtr Chart
Click to enlarge
Net Sales Rs m1,3811,0661,3561,1041,0931,1781,175937 
Other income Rs m2233111151341091007379 
Turnover Rs m1,6041,3771,4711,2381,2021,2781,2481,016 
Expenses Rs m1,4161,2421,2219051,1451,2061,085827 
Gross profit Rs m-35-176135199-52-2890110 
Depreciation Rs m7710932313335 
Interest Rs m1500012171719 
Profit before tax Rs m1661282403241324114136 
Tax Rs m66341111295763768 
Profit after tax Rs m100941291958-527768 
Gross profit margin %-2.5-16.510.018.0-4.8-2.47.711.8 
Effective tax rate %39.726.946.439.739.7317.532.150.0 
Net profit margin %7.28.89.517.70.7-4.46.67.2 
Diluted EPS Rs 0.3 0.3 0.4 0.6 0.0 -0.2 0.2 0.2  
Diluted EPS (TTM) Rs 2.4 1.9 1.8 1.5 1.3 0.8 0.7 0.3  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: Novartis 3QFY20 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   ELDER PHARMA  CIPLA  AJANTA PHARMA  INDOCO REMEDIES  DISHMAN PHARMA  

Compare NOVARTIS With:   ELDER PHARMA  CIPLA  AJANTA PHARMA  INDOCO REMEDIES  DISHMAN PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; Smallcap Stocks Outperform(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended marginally lower.

Views on news

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation (Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer (Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Oct 22, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NOVARTIS

NOVARTIS - TEVA PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS